28th Mar 2025 07:00
To: Stock Exchange Date: 28 March 2025 | |
CT Private Equity Trust PLC
LEI: 2138009FW98WZFCGRN66
Preliminary Announcement for the Year Ended 31 December 2024CT Private Equity Trust PLC today announces its unaudited financial results for the year ended 31 December 2024.
Financial Highlights
· Share price total return for the year of 10.9 per cent for the Ordinary Shares.*
· NAV of 706.03 pence per Ordinary Share reflecting a total return for the year of 4.6 per cent.*
· Total quarterly dividends for the year of 28.04 pence per Ordinary Share. Quarterly dividend of 7.01 pence per Ordinary Share to be paid on 30 April 2025.
· Dividend yield of 5.7 per cent based on the year-end share price.* £146 million of dividends returned to Shareholders since January 2013. This represents a ten-year compound annual growth rate of 10.0%.
· Realisations for 2024 of £108.6 million, an increase of 76% in comparison to 2023.
· As at 31 December 2024 net debt was £76.5 million equivalent to a gearing level of 13.2%.
· The Company enters 2025 with a strong balance sheet and a well-diversified portfolio of high growth and dynamic companies.
*see Alternative Performance Measures
Chairman's Statement
Fellow Shareholders,
This report is for the year ended 31 December 2024. The NAV per share at the year-end was 706.03p (2023: 702.50p). Taking account of the dividends received by Shareholders during this year your Company achieved a net asset value ("NAV") total return of 4.6 per cent (2023: 2.8 per cent).
The share price at the year-end was 488.00p per share (2023: 468.00p). The share price total return for the year was 10.9 per cent (2023: 17.6 per cent). This compares to a total return from the FTSE All-Share Index for 2024 of 9.5 per cent (2023: 7.9 per cent).
The share price discount as at 31 December 2024 was 30.9 per cent (2023: 33.4%)*.
During the year the Company made new investments, either through funds or as co-investments, totalling £58.7 million. Realisations and associated income totalled £108.6 million. Outstanding undrawn commitments at the year-end were £193.0 million of which £27.0 million was to funds where the investment period had expired.
Approximately 91 per cent of the valuation by value is based on 31 December 2024 valuations and 9 per cent on September 2024 valuations.
The Company's performance fee arrangements contain a hurdle rate, calculated over rolling three-year periods, of an IRR of 8.0 per cent per annum. The annual IRR of the NAV for the three-year period ended 31 December 2024 was 7.7 per cent and, consequently, a performance fee is not payable to the Manager, in respect of 2024.
Capital Allocation
Since its foundation, the Company has been both innovative and proactive with regard to its capital strategy. The Board regularly reviews the Company's capital allocation and seeks to balance the benefits of an immediate enhancement to NAV from share buybacks against the anticipated longer-term returns from new investment.
Dividends
The Company's innovative dividend policy was introduced in 2012 and remains the cornerstone of the Company's capital allocation strategy. The Company pays a substantial dividend from realised profits allowing Shareholders to participate, to some degree, directly in the proceeds of the steady stream of private equity realisations which the Company achieves. Since 1 January 2013 the Company has returned £146 million of dividends to Shareholders. This represents a ten-year compound annual growth rate of 10.0 per cent. This policy provides for a steadily growing dividend with downside protection. Your Board is fully committed to maintaining this approach for the foreseeable future.
The Company's quarterly dividends are payable in respect of the quarters ended 31 March, 30 June, 30 September and 31 December and are paid in the following July, October, January and April respectively. As Shareholders do not have an opportunity to approve a final dividend at each Annual General Meeting, Shareholders are asked to approve the Company's dividend policy at the forthcoming Annual General Meeting.
In accordance with the Company's stated dividend policy, the Board recommends a further quarterly dividend of 7.01 pence per Ordinary Share, payable on 30 April 2025 to Shareholders on the register on 11 April 2025 and an ex-dividend date of 10 April 2025. Total dividends paid for the year therefore amount to 28.04 pence per Ordinary Share equivalent to a dividend yield of 5.7 per cent at the year-end.
Share Buybacks
The Company does not have a stated discount management policy. However, the Board recognises the importance of movements in the Company's discount upon the return that Shareholders receive and monitors closely the discount's absolute and relative levels. At the Annual General Meeting held on 29 May 2024, the Board sought and received from Shareholders the authority to buy back up to 14.99% of the Company's share capital. Buybacks can only be made at a cost per share which is below the prevailing NAV.
During the year ended 31 December 2024 the Company bought back, to be held in treasury, a total of 1.25 million shares. This equated to 1.7% of the shares in issue, excluding those held in treasury, at 31 December 2023. The shares were bought back in two tranches at 460 pence per share and cost, in total, £5.8 million.
These shares are held in treasury to allow the Company to re-issue them quickly and cost effectively. At last year's AGM the Board sought and received the authority from Shareholders to re-issue treasury shares or issue new shares, subject to limitations on the number and price. Treasury shares can only be re-issued and new shares issued at a price which would not dilute the NAV of existing Shareholders.
The Board seeks renewal of these buyback and reissuance authorities at the AGM to be held on 29 May 2025.
The Company continues to appraise the relative merits of using capital for share buybacks versus new investment whilst protecting and growing the dividend.
Financing
To reflect the growth in the size of the Company during February 2024, the Company entered into a revised loan agreement with RBSI and State Street.
The revised loan agreement increased the €25 million term loan with RBSI to €60 million and retained the revolving credit facility with RBSI and State Street at £95 million. The term of the agreement, which was due to expire in June 2024, was extended to February 2027.
The Company had net debt at 31 December 2024 of £76.5 million (31 December 2023: £87.2 million). This represents gearing of 13.2% (31 December 2023: 14.6%). Approximately half of the Company's borrowing facilities are unused with plenty of headroom.
Annual General Meeting
The Annual General Meeting ("AGM") will be held at 13.00 on 29 May 2025 at the offices of Columbia Threadneedle Investments, Cannon Place, Cannon Street, London EC4N 6AG. This will be followed by a presentation by Hamish Mair, the Company's Investment Manager on the Company and its investment portfolio.
For Shareholders who are unable to attend the meeting, any questions they may have regarding the resolutions proposed at the AGM or the performance of the Company can be directed to a dedicated email account, [email protected], by Thursday 22 May 2025. The Board will endeavour to ensure that questions received by such date will be addressed at the meeting. The meeting will be recorded and will be available to view on the Company's website, ctprivateequitytrust.com, shortly thereafter.
In addition, the AGM and Investment Manager presentation will be broadcast live on the Investor Meet Company platform. This broadcast is open to all existing and potential Shareholders to view. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 9.00am on 28 May 2025. Investors can sign up to Investor Meet Company for free and add to meet CT Private Equity Trust plc via www.investormeetcompany.com/ct-private-equity-trust-plc/register-investor. Investors who already follow CT Private Equity Trust plc on the Investor Meet Company platform will automatically be invited.
All Shareholders that cannot attend in person are encouraged to complete and submit their Form of Proxy or Form of Direction in advance of the meeting to ensure that their votes will count.
Review and Outlook
We have experienced significant changes over the last five years. Post pandemic markets are significantly more volatile. Across the developed world public debt is at record levels, a legacy of the pandemic and the earlier period of ultra-low interest rates. According to the Institute of International Finance global debt reached a record high of $318 trillion in 2024. The debt burden has been further increased by a normalisation of interest rates, further stretching public budgets many of which were already challenged by aging populations and climate change. Geopolitical risks have also increased significantly, with Russia's invasion of Ukraine, war in the Middle East, an increasingly assertive China and a significant shift in US foreign policy. Meanwhile listed markets have become increasingly concentrated, in a few very large US technology stocks (at the end of 2024 the 'magnificent seven', Nvidia, Apple, Amazon, Alphabet, Meta, Microsoft and Tesla, accounted for nearly a quarter of the MSCI World index) increasing systemic risk.
As described in the Investment Manager's Review your Company's portfolio has coped exceptionally well with these challenges, providing Shareholders with both capital growth and income while mitigating risk through strong diversification. Over the last five years your Company has delivered an impressive NAV total return of 105.9%. The Company's long term track record was recognised by The Association of Investment Companies ("the AIC"), which named CT Private Equity Trust PLC as the ninth best performing investment trust over the last ten years in February 2025. Having paid a steadily increasing dividend for over 12 years the Company is also recognised as an AIC Next Generation Dividend Hero. To qualify an investment trust requires sustained growth in annual dividends for ten years. This combination of strong growth and income yield puts your CT Private Equity Trust PLC in rare company.
This excellent performance is based on the strength of the underlying fundamentals for our investee companies which, supported by our investment partners, have adapted to changing environments and recorded impressive growth in revenues and profits. Meanwhile the flow of investment opportunities that your managers appraise remains very strong reflecting the breadth of the mid-market universe we address and the depth of our networks in these markets internationally. The outlook for 2025 remains uncertain, however your Company remains well positioned to deliver further gains to Shareholders whilst laying the foundations for future growth.
Richard Gray
Chairman
*see Alternative Performance Measures
Investment Manager's Review
Introduction
2024 has seen the private equity market stabilise after what has been the most challenging period for the industry since the great financial crisis. During the year interest rates and inflation finally reduced and economic growth in many of our key markets stabilised. As a result, investment and exit activity began to recover after two years of decline. According to Bain & Company global buyout investment and exit value increased 37% and 34% respectively in 2024.
This increased activity can be seen in the increase in realisations received by the Company during the year, which totalled £108.6 million, up 76% on the prior year. Markets however remain uncertain and shifting, and a full recovery is yet to take hold.
New Investments
Dealflow for new funds and co-investments remains very strong, with hundreds of investment opportunities reviewed over the year. These come from both long-term investment partners and others who are newer to our network.
The total invested in funds and co-investments in the year was £58.7 million, down from £110.8 million in 2023. We remain highly selective in light of the continued challenges in exit markets.
Five new fund commitments were made in the year. £10.0 million was committed to August Equity VI, the latest in a series of commitments to this accomplished lower mid-market UK buyout specialist.
£5.0 million was committed to Inflexion Enterprise Fund VI, the latest in a series of Inflexion funds focusing on lower mid-market buyouts in the UK and Northern Europe.
£6.0 million was committed to Corran Environmental Fund II, a UK lower mid-market growth fund with a focus on clean energy and environmental companies. The fund's cornerstone investment Vital Energi is the UK's leading district heating and energy efficiency specialist which also owns and operates an energy-from-waste plant at Drakelow, Derbyshire.
€5.0 million was committed to the Agilitas Human Investment Fund a pan-European fund with an explicit investment objective of helping people that are disadvantaged or in need. We have invested with Agilitas both through funds and co-investments several times over the years.
€4.0 million has been committed to ARCHIMED MED Rise. ARCHIMED is a leading France headquartered healthcare specialist with whom we have invested several times. This fund targets buyouts of small healthcare businesses operating within attractive niches globally.
There was one new co-investment plus several significant follow-on investments primarily to fund add-on acquisitions.
A total of £4.0 million was invested in Accounts IQ, a B2B cloud-based accounting software provider for mid-sized companies in the UK and Ireland. The investment is led by Axiom I, the enterprise software focussed lower mid-market fund, which drew £1.4 million for the investment, alongside which we co-invested a further £2.6 million.
£4.2 million was invested in Breeze Group, the parent company of Contained Air Solutions (the Manchester-based manufacturer of microbiological safety cabinets) to fund complementary acquisitions. Amercare is a UK-based designer and supplier of isolators for medical and pharmaceutical applications, including cell therapy and radiopharmacy. BioSpherix is a US-based provider of novel cleanroom grade containment solutions aimed at the cell therapy market. Its products control the environmental conditions to optimise cell health and reproducibility.
£2.2 million was invested in MedSpa, the Canada-based chain of aesthetics clinics to finance three acquisitions. £1.6 million was invested in Texas based digital payment solutions provider Aurora Payment Solutions. £1.0 million was invested in Utimaco, the German encryption and cybersecurity solutions provider. £0.7 million of additional working capital was invested in the US focussed Mexican restaurant chain Rosa Mexicano. £0.5 million was invested in Polaris Software, the UK based provider of compliance software to police and local authorities. £0.5 million was invested in GT Medical, the developer of the brain cancer radiotherapy device GammaTile.
The funds in our portfolio have made several new investments which cover various sectors and geographies. Below is a selection of the more material.
In the UK Corran Environmental II called £3.7 million for investment in district heating and environmental efficiency specialist Vital Energi. SEP VI invested £0.7 million in Braincube, the French industrial internet of things software company which specialises in optimising manufacturing processes, and £0.9 million in Cora, an Irish software company specialising in project management software for the aerospace, defence, healthcare and life sciences sectors. Kester Capital III called £1.2 million for an investment in The Boundary, a creative agency providing computer generated imagery and marketing materials to the global real estate industry and £0.5 million for GXP Exchange, a leading provider of clinical/pharmacovigilance audit and related consulting services to the pharmaceutical and biotech sectors. FPE III called £0.8 million for an investment in Clearstate, a leading provider of market data to the MedTech sector, which is a carve out from The Economist Group, and £1.0 million for Vanda Research, a provider of specialist research and data products for hedge funds and investment banks. Piper Private Equity VII invested £0.7 million in Inside Travel Group, a leading Asia-focused 'cultural adventure' travel brand.
In Europe Corsair VI, the financial services specialists, called £1.1 million for MJM, a leading independent commercial insurance broker in Poland. Also in Poland, Avallon III called £0.6 million for MPPK, a pet food company. Vaaka IV called £0.9 million to invest in Finnish IT infrastructure provider Tietokeskus alongside a continuation vehicle. We had existing exposure to this business through the commitment to Vaaka II. In Italy, Wisequity VI called £1.1 million for Serbios a leading Italian bio-controls company (providing biological alternatives to pesticides and agrochemicals). This is the first acquisition within Greenexta, a newly established buy-and-build platform for natural solutions for agriculture. Wisequity VI also called £0.6 million for Case Della Piada, a leading Italian producer of flatbreads. Inflexion Buyout Fund VI called £1.6 million for two European investments. DSS+ (£0.8 million) is a Swiss health and safety focussed management consultancy and Nomentia (£0.7 million), a Finland-based cash and treasury management software provider. Hg Saturn 3 called £0.5 million for GGW, a European insurance brokerage platform for SMEs in Germany's Mittelstand. Corpfin V invested £0.5 million in Groupo Versus, which provides training and education for military police, national police and prison officers in Spain.
In North America Procuritas VII called £0.4 million for Precision Biologic, a Canadian supplier of high-quality reagents used for haemostasis (blood coagulation) diagnostics serving a mainly North American customer base of over a thousand laboratories, hospitals, universities and research centres. MidOcean VI invested £0.4 million in SI Solutions a US provider of engineering, testing, compliance and maintenance services for power and critical infrastructure markets. Corsair VI called a further £0.6 million for a follow-on investment in HungerRush (restaurant point-of-sale software) as part of a debt restructuring to increase flexibility on its financial covenants and lower debt service costs. Graycliff IV invested £0.5 million in Diamond Chemical, a manufacturer of cleaning and sanitation chemicals serving hospitality, food service, commercial laundry, and other end markets.
Realisations
After a strong recovery in the second and third quarter realisations slowed in the final quarter of the year. The total for the year was £108.6 million, up 76% on the £61.7 million achieved in 2023.
There were three co-investments realised in the year. In April Kester Capital sold large format pet retailer Jollyes to TDR Capital returning £18.6 million (4.2x cost and 27% IRR). The company doubled EBITDA and built its chain from 64 stores to 100 during the hold period.
In May Buckthorn Partners sold Aberdeen-based oil and gas wellbore plug and abandonment specialist Coretrax to large, listed energy services group Expro returning £13.9 million (1.7x cost and 11% IRR). A reasonable result given the volatility in energy markets since the investment was made in 2018.
Finally in August Kester Capital sold ATEC to Perwyn. The combined proceeds from both the co-investment, the proportion held in the GCP Europe II fund and the proportion held through The Aurora Fund position was £18.5 million. ATEC is a specialist insurance broker and general manager for niche areas such as caravans, beach huts and boats. It has grown profits almost fourfold during the holding period and significantly expanded its product offering.
There was also a steady flow of excellent exits from within our fund investments. In the UK August Equity IV returned £3.5 million through the sale of Agilio, the healthcare compliance software company, achieving an exceptional return of 9.2x cost and an IRR of 72%. Apiary exited TAG, the leading travel management company servicing the global live music and entertainment industry, which was hard hit by the Covid pandemic, returning £1.5 million (4.0x cost and 29% IRR). RJD Fund III exited veterinary education company Improve International returning £1.4 million (3.3x cost and 49% IRR). Inflexion Enterprise Fund IV sold ATG, a global automative data and software company, returning £0.9 million, an impressive 6.8x cost and 39% IRR over the five-year hold and pet supplements company Lintbells realising £1.0 million (5.5x cost and an IRR of 34%). Inflexion Enterprise Fund V returned £1.2 million from the sale of commercial insurance broker DR&P for an excellent 11.2x cost and 77% IRR.
In the Netherlands Bencis V had an exceptional year, returning £6.6 million from a series of excellent exits. It returned £1.9 million (7.2x cost and 49% IRR) from the sale of Vecos, a cloud-based locker management system provider; £1.9 million (13.9x cost and 61% IRR) from the sale of Kooi, a mobile security systems provider; £1.1 million (7.2x cost and 35% IRR) from the sale of Tech Tribes, a digital transformation consultancy company; £0.9 million (4.7x cost and 36% IRR) from the sale of Ceban Pharmaceuticals, a business which specialises in compounding drugs in different formats and owns a major pharmacy chain Medsen; and £0.9 million (7.5x cost and 33% IRR) from the sale of Olyslager, a supplier of lubricant data for companies in the oil industry.
In the Nordics Summa II sold Olink to Thermo Fisher returning £3.6 million (9.9x cost and an IRR of 67%). Olink has developed a technology for analysing proteins which is used in human protein biomarker research. Meanwhile Summa I returned £1.7 million (5.6x cost and 31% IRR) through the sale of Pagero, a procure to pay software as a service company, to Thomson Reuters.
In France, Montefiore IV returned £3.1 million. £2.5 million was returned from the sale of EDG (digital services for French companies) and Groupe Premium (life and pension insurance broker) to a continuation vehicle and £0.5 million (2.9x cost and 21% IRR) was returned from Cruiseline, the online travel agent for cruises; this follows the successful resolution of a long running legal case after Abénex Capital pulled out of the agreed purchase of the business at the onset of the Covid pandemic. Chequers Capital XVII also returned £1.5 million (3.6x cost) from the sale of Somacis, a designer and manufacturer of high mix, low volume printed circuit boards.
Italian fund Nem Impresse made its final exit with the sale of business processing and outsourcing company Kauri yielding £2.1 million. Also in continental Europe, DBAG VIII returned £1.7 million (3.2x cost and 63% IRR) from the sale of in-tech a provider of software development, testing and validation.
In the US Graycliff continued its excellent run of exits returning £7.5 million in the year from fund III and IV. The sale of EMC, a switches and transformers manufacturer, achieved another exceptional outcome and returned £2.5 million (8.2x cost and an IRR of 146%); sweeteners manufacturer Ingredients Plus returned £2.1 million (3.3x cost, 34% IRR); the sale of Landmark Structures, elevated water towers, returned £1.9 million (7.8x cost and 132% IRR); and Ballymore, the designer and manufacturer of safety material handling equipment, returned £1.1 million (4.0x cost and 60% IRR).
Valuation Movements
Valuations were broadly flat in the first three quarters of the year, before increasing in the final quarter. Over the full year the portfolio was up £37.6 million (6.2%) before foreign exchange movements (-1.5%) and £28.4 million (4.7%) after FX.
The largest uplift was +£5.9 million for ATEC, the specialist insurer, which Kester sold in August to private equity house Perwyn. This was followed by an uplift of +£5.8 million in British lifestyle clothing and accessories retailer Weird Fish, which continues to perform very strongly under new CEO David Butler and recorded record profits in 2024. Inflexion Strategic Partners is up £4.6 million, reflecting impressive growth in assets under management. Other notable uplifts in the co-investment portfolio include encryption and cybersecurity solutions provider Utimaco (+£2.9 million); Denmark-based care company Habitus (+£2.4 million); social housing repairs and maintenance provider CARDO Group (+£2.0 million).
Within the funds portfolio uplifts include Axiom I (+£1.7 million), Inflexion Supplemental Fund V (+£1.7 million), Bencis V (+£1.5 million) due to the previously mentioned strong realisations and FPE II (+£1.5 million) due to several uplifts across the portfolio.
Write-downs were dominated by companies that have experienced a negative long-term impact from the Covid pandemic. Some consumer businesses experienced very rapid growth during the pandemic, which has since moderated due to reduced consumer confidence, changing priorities, or because orders were pulled forward by the pandemic and lockdowns. As previously reported Leader, the electric bike company in Bulgaria, is operating in a challenging market due to reduced consumer demand. The sector is expected to return to growth, however only after a serious destocking phase which is affecting the whole industry. The valuation is down by £2.4 million. Omlet, the premium pet products brand, continues to experience difficult trading conditions and weaker consumer demand and was down £2.0 million. Rosa Mexicano, the Mexican restaurant chain, has experienced weaker trading and is down by £1.6 million. In all cases management has been strengthened, turnaround plans are in place, and we are seeing encouraging signs of recovery.
Meanwhile changes to working practices have impacted companies such as Muraflex, which provides office renovations in North America, leading to a £2.6 million write-down in Aliante 3 and Agilico, which provides printers and scanners to offices, which is down £2.1 million.
Financing
During the year there was a net inflow of £49.9 million from the portfolio, as realisations of £108.6 million exceeded investments of £58.7 million. At the end of 2024 the net debt of the Company was £76.5 million which was comfortably within the limits of the borrowing capacity and represented gearing of 13.2%.
As previously reported, in April the Company bought back 1.25 million shares at 460p which amounted to 1.7% of the issued share capital, excluding shares held in treasury, at a cost of £5.8 million. The Company continues to appraise the relative merits of using capital for share buy-backs versus new investment whilst protecting and growing the dividend.
Outlook
2024 saw a good recovery in realisations, with the Company receiving £108.6 million in the year, an increase of 76% on 2023, representing significant positive cashflow for the Company. This is only the third year in the Company's history that annual realisations have exceeded £100 million (though this is largely due to the strong growth of the Company). Realisations during the year were 18% of opening portfolio value, a good uplift on the prior year, but still below the 10-year average of 25%. Further growth in realisations and liquidity are essential for the continued recovery of the private equity market (and in particular fundraising) and are a strong focus for private equity managers. As exits are typically at a significant premium to holding value an uptick in realisations should also feed through into strong returns.
Most of the conditions required for a recovery in 2025 appear to be in place. Interest rates and inflation have moderated and are expected to decrease further in many markets, debt availability and pricing has improved, and there is plenty of capital in private equity funds that managers are keen to invest. The key to building the recovery's momentum is business and investor confidence. This is threatened by persistent uncertainty: geopolitical tensions are high, wars continue in the Middle East and Ukraine, new trade wars threaten, and radical changes to US foreign policy require countries across the globe to adapt. There are likely to be significant changes in 2025. While this presents risk it also provides significant opportunities for those able to adjust and to act with confidence.
As the most engaged and aligned of asset classes, private equity is uniquely positioned to rapidly adapt to changing environments, with private equity managers and company management able to work together to deliver transformational change and deliver growth. The Company has consistently demonstrated its ability to outperform in uncertain times and to deliver a strong and growing dividend. We enter 2025, with a strong balance sheet and a well-diversified portfolio of high growth and dynamic companies.
Hamish Mair
Investment Manager
CT Investment Business Limited
Portfolio Summary
Portfolio Distribution at 31 December 2024 | % of Total 31 December 2024 | % of Total 31 December 2023 |
Buyout Funds - Pan European* | 11.6 | 10.5 |
Buyout Funds - UK | 19.2 | 16.2 |
Buyout Funds - Continental Europe† | 15.5 | 18.2 |
Secondary Funds | - | 0.1 |
Private Equity Funds - USA | 4.4 | 5.0 |
Private Equity Funds - Global | 2.7 | 1.7 |
Venture Capital Funds | 4.5 | 3.7 |
Direct Investments/Co-investments | 42.1 | 44.6 |
100.0 | 100.0 | |
* Europe including the UK. † Europe excluding the UK. |
|
|
|
|
|
|
Ten Largest Holdings As at 31 December 2024 | Total Valuation £'000 | % of Total Portfolio |
Inflexion Strategic Partners | 19,296 | 3.3 |
Sigma | 16,031 | 2.7 |
Weird Fish | 15,118 | 2.6 |
August Equity Partners V | 12,096 | 2.1 |
TWMA | 12,087 | 2.1 |
Utimaco | 10,661 | 1.8 |
San Siro | 10,460 | 1.8 |
Aurora Payment Solutions | 9,996 | 1.7 |
Stirling Square Capital II | 9,554 | 1.6 |
Inflexion Supplemental V | 9,459 | 1.6 |
124,758 | 21.3 | |
Portfolio Holdings
| Investment | Geographic Focus
| Total Valuation £'000 | % of Total Portfolio | ||||
| Buyout Funds - Pan European | |||||||
| Stirling Square Capital II | Europe | 9,554 | 1.6 | ||||
| Apposite Healthcare III | Europe | 9,321 | 1.6 | ||||
| F&C European Capital Partners | Europe | 8,867 | 1.5 | ||||
| Apposite Healthcare II | Europe | 8,248 | 1.4 | ||||
| Summa III | Northern Europe | 3,269 | 0.6 | ||||
| MED II | Western Europe | 3,060 | 0.5 | ||||
| Agilitas 2015 Fund | Northern Europe | 3,037 | 0.5 | ||||
| Verdane XI | Northern Europe | 2,941 | 0.5 | ||||
| Wisequity VI | Italy | 2,910 | 0.5 | ||||
| Magnesium Capital 1 | Europe | 2,430 | 0.4 | ||||
| Astorg VI | Western Europe | 2,239 | 0.4 | ||||
| Volpi III | Northern Europe | 2,104 | 0.4 | ||||
| MED Platform II | Global | 2,068 | 0.3 | ||||
| KKA II | Europe | 1,573 | 0.3 | ||||
| ARCHIMED MED III | Global | 1,452 | 0.3 | ||||
| Agilitas 2020 Fund | Europe | 1,228 | 0.2 | ||||
| Verdane Edda III | Northern Europe | 1,059 | 0.2 | ||||
| TDR Capital II | Western Europe | 903 | 0.2 | ||||
| TDR II Annex Fund | Western Europe | 791 | 0.1 | ||||
| Inflexion Partnership III | Europe | 526 | 0.1 | ||||
| Agilitas 2024 HIF | Europe | 69 | - | ||||
| Total Buyout Funds - Pan European | 67,649 | 11.6 | |||||
|
Buyout Funds - UK | |||||||
| Inflexion Strategic Partners | United Kingdom | 19,296 | 3.3 | ||||
| August Equity Partners V | United Kingdom | 12,096 | 2.1 | ||||
| Inflexion Supplemental V | United Kingdom | 9,459 | 1.6 | ||||
| Inflexion Buyout Fund V | United Kingdom | 6,795 | 1.2 | ||||
| Apiary Capital Partners I | United Kingdom | 6,450 | 1.1 | ||||
| Inflexion Buyout Fund VI | United Kingdom | 5,217 | 0.9 | ||||
| FPE Fund III | United Kingdom | 5,006 | 0.9 | ||||
| Axiom 1 | United Kingdom | 4,983 | 0.8 | ||||
| FPE Fund II | United Kingdom | 4,866 | 0.8 | ||||
| August Equity Partners IV | United Kingdom | 4,497 | 0.8 | ||||
| Kester Capital II | United Kingdom | 4,468 | 0.8 | ||||
| Corran Environmental II | United Kingdom | 4,207 | 0.7 | ||||
| Inflexion Partnership Capital II | United Kingdom | 3,974 | 0.7 | ||||
| Piper Private Equity VI | United Kingdom | 3,884 | 0.7 | ||||
| Piper Private Equity VII | United Kingdom | 3,266 | 0.6 | ||||
| Kester Capital III | United Kingdom | 2,372 | 0.4 | ||||
| Inflexion Buyout Fund IV | United Kingdom | 2,225 | 0.4 | ||||
| Inflexion Enterprise Fund V | United Kingdom | 2,116 | 0.4 | ||||
| Inflexion Supplemental IV | United Kingdom | 1,449 | 0.2 | ||||
| Inflexion Enterprise Fund IV | United Kingdom | 1,444 | 0.2 | ||||
| Primary Capital IV | United Kingdom | 1,440 | 0.2 | ||||
| Inflexion Partnership Capital I | United Kingdom | 1,266 | 0.2 | ||||
| RJD Private Equity Fund III | United Kingdom | 467 | 0.1 | ||||
| Horizon Capital 2013 | United Kingdom | 377 | 0.1 | ||||
| GCP Europe II | United Kingdom | 201 | - | ||||
| Piper Private Equity V | United Kingdom | 163 | - | ||||
| August Equity Partners VI | United Kingdom | 111 | - | ||||
| Dunedin Buyout Fund II | United Kingdom | 5 | - | ||||
| Total Buyout Funds - UK | 112,100 | 19.2 | |||||
|
|
| ||||||
| ||||||||
| ||||||||
| Investment | Geographic Focus
| Total Valuation £'000 | % of Total Portfolio | ||||
| Buyout Funds - Continental Europe | |||||||
| Aliante Equity 3 | Italy | 8,366 | 1.4 | ||||
| Avallon MBO Fund III | Poland | 6,352 | 1.1 | ||||
| Vaaka III | Finland | 5,828 | 1.0 | ||||
| DBAG VII | DACH | 5,714 | 1.0 | ||||
| Bencis V | Benelux | 5,232 | 0.9 | ||||
| Capvis III CV | DACH | 4,654 | 0.8 | ||||
| Montefiore V | France | 4,252 | 0.7 | ||||
| Verdane Edda | Nordic | 4,224 | 0.7 | ||||
| DBAG VIII | DACH | 4,113 | 0.7 | ||||
| Corpfin V | Spain | 4,086 | 0.7 | ||||
| Procuritas VII | Nordic | 3,827 | 0.7 | ||||
| Procuritas VI | Nordic | 3,728 | 0.6 | ||||
| Chequers Capital XVII | France | 3,675 | 0.6 | ||||
| ARX CEE IV | Eastern Europe | 3,003 | 0.5 | ||||
| Procuritas Capital IV | Nordic | 2,564 | 0.4 | ||||
| Italian Portfolio | Italy | 2,487 | 0.4 | ||||
| Vaaka IV | Finland | 2,335 | 0.4 | ||||
| Montefiore IV | France | 2,042 | 0.4 | ||||
| Aurica IV | Spain | 1,936 | 0.3 | ||||
| Capvis IV | DACH | 1,794 | 0.3 | ||||
| Corpfin Capital Fund IV | Spain | 1,591 | 0.3 | ||||
| Summa II | Nordic | 1,417 | 0.3 | ||||
| Summa I | Nordic | 1,396 | 0.2 | ||||
| DBAG VIIB | DACH | 1,036 | 0.2 | ||||
| Portobello Fund III | Spain | 1,007 | 0.2 | ||||
| DBAG VIIIB | DACH | 946 | 0.2 | ||||
| DBAG Fund VI | DACH | 828 | 0.2 | ||||
| Chequers Capital XVI | France | 621 | 0.1 | ||||
| Vaaka II | Finland | 374 | 0.1 | ||||
| Ciclad 5 | France | 295 | 0.1 | ||||
| PineBridge New Europe II | Eastern Europe | 246 | - | ||||
| Gilde Buyout Fund III | Benelux | 88 | - | ||||
| Procuritas Capital V | Nordic | 71 | - | ||||
| Capvis III | DACH | 50 | - | ||||
| Montefiore Expansion | France | 47 | - | ||||
| DBAG Fund V | DACH | 5 | - | ||||
| Total Buyout Funds - Continental Europe | 90,230 | 15.5 | |||||
| ||||||||
| ||||||||
|
| |||||||
| ||||||||
Investment | Geographic Focus
| Total Valuation £'000 | % of Total Portfolio |
| ||||
Private Equity Funds - USA
Blue Point Capital IV | North America | 7,475 | 1.3 |
Level 5 Fund II | United States | 3,296 | 0.6 |
Camden Partners IV | United States | 3,218 | 0.5 |
Purpose Brands (Level 5) | United States | 3,104 | 0.5 |
MidOcean VI | United States | 2,257 | 0.4 |
Blue Point Capital III | North America | 2,065 | 0.3 |
Stellex Capital Partners | North America | 1,729 | 0.3 |
Graycliff IV | North America | 1,601 | 0.3 |
Graycliff III | United States | 1,061 | 0.2 |
Blue Point Capital II | North America | 162 | - |
Total Private Equity Funds - USA | 25,968 | 4.4 | |
| |||
| |||
Private Equity Funds - Global | |||
Corsair VI | Global | 8,424 | 1.4 |
Hg Saturn 3 | Global | 4,951 | 0.9 |
Hg Mercury 4 | Global | 897 | 0.2 |
PineBridge GEM II | Global | 654 | 0.1 |
F&C Climate Opportunity Partners | Global | 421 | 0.1 |
AIF Capital Asia III | Asia | 111 | - |
PineBridge Latin America II | South America | 59 | - |
Warburg Pincus IX | Global | 10 | - |
Total Private Equity Funds - Global | 15,527 | 2.7 | |
Venture Capital Funds | |||
SEP V | Global | 9,383 | 1.6 |
MVM V | Global | 4,413 | 0.8 |
SEP VI | Europe | 3,140 | 0.5 |
MVM VI | Global | 2,950 | 0.5 |
Kurma Biofund II | Europe | 2,735 | 0.5 |
Northern Gritstone | United Kingdom | 1,697 | 0.3 |
SEP IV | United Kingdom | 1,190 | 0.2 |
Pentech Fund II | United Kingdom | 377 | 0.1 |
SEP II | United Kingdom | 260 | - |
SEP III | United Kingdom | 60 | - |
Environmental Technologies Fund | Europe | 57 | - |
Life Sciences Partners III | Western Europe | 31 | - |
Total Venture Capital Funds | 26,293 | 4.5 | |
Secondary Funds | |||
The Aurora Fund | Europe | 205 | - |
Total Secondary Funds | 205 | - | |
|
|
|
|
Investment | Geographic Focus
| Total Valuation £'000 | % of Total Portfolio |
Direct Investments/Co-investments | |||
Sigma | United States | 16,031 | 2.7 |
Weird Fish | United Kingdom | 15,118 | 2.6 |
TWMA | United Kingdom | 12,087 | 2.1 |
Utimaco | DACH | 10,661 | 1.8 |
San Siro | Italy | 10,460 | 1.8 |
Aurora Payment Solutions | United States | 9,996 | 1.7 |
Amethyst Radiotherapy | Europe | 8,786 | 1.5 |
Breeze Group (CAS) | United Kingdom | 7,998 | 1.4 |
Cyclomedia | Netherlands | 7,828 | 1.3 |
Asbury Carbons | North America | 7,342 | 1.3 |
CARDO Group | United Kingdom | 6,955 | 1.2 |
Velos IoT (JT IoT) | United Kingdom | 6,853 | 1.2 |
Prollenium | North America | 6,608 | 1.1 |
Swanton | United Kingdom | 6,589 | 1.1 |
Habitus | Denmark | 6,395 | 1.1 |
Orbis | United Kingdom | 6,282 | 1.1 |
Family First | United Kingdom | 6,113 | 1.1 |
Cyberhawk | United Kingdom | 5,987 | 1.0 |
Rosa Mexicano | United States | 5,902 | 1.0 |
Polaris Software (StarTraq) | United Kingdom | 5,806 | 1.0 |
123Dentist | Canada | 4,878 | 0.8 |
Cybit (Perfect Image) | United Kingdom | 4,874 | 0.8 |
Braincube | France | 4,652 | 0.8 |
MedSpa Partners | Canada | 4,632 | 0.8 |
LeadVenture | United States | 4,510 | 0.8 |
AccuVein | United States | 4,273 | 0.7 |
Walkers Transport | United Kingdom | 4,172 | 0.7 |
1Med | Switzerland | 4,163 | 0.7 |
Dotmatics | United Kingdom | 4,155 | 0.7 |
PathFactory | Canada | 3,649 | 0.6 |
Collingwood Insurance Group | United Kingdom | 3,435 | 0.6 |
Vero Biotech | United States | 3,366 | 0.6 |
GT Medical | United States | 3,307 | 0.6 |
Educa Edtech | Spain | 3,035 | 0.5 |
AccountsIQ | Ireland | 2,477 | 0.4 |
Neurolens | United States | 2,336 | 0.4 |
Alessa (Tier1 CRM) | Canada | 2,083 | 0.4 |
Omlet | United Kingdom | 2,039 | 0.4 |
OneTouch | United Kingdom | 2,003 | 0.3 |
Agilico (DMC Canotec) | United Kingdom | 1,734 | 0.3 |
Bomaki | Italy | 1,469 | 0.3 |
Rephine | United Kingdom | 1,289 | 0.2 |
Avalon | United Kingdom | 1,234 | 0.2 |
Ambio Holdings | United States | 1,211 | 0.2 |
Leader96 | Bulgaria | 748 | 0.1 |
Jollyes | United Kingdom | 397 | 0.1 |
TDR Algeco/Scotsman | Europe | 207 | - |
Total Direct - Investments/Co-investments | 246,125 | 42.1 | |
Total Portfolio | 584,097 | 100.0 |
CT Private Equity Trust PLC
Statement of Comprehensive Income for the
year ended 31 December 2024
| (Unaudited)
| |||
Revenue £'000 | Capital £'000 | Total £'000
| |
| Income | |||
Gains on investments held at fair value | - | 25,144 | 25,144 |
Exchange gains | - | 5,055 | 5,055 |
Investment income | 3,270 | - | 3,270 |
Other income | 961 | - | 961 |
| Total income | 4,231 | 30,199 | 34,430 |
| Expenditure | |||
Investment management fee - basic fee | (489) | (4,404) | (4,893) |
Investment management fee - performance fee | - | - | - |
Other expenses | (1,226) | - | (1,226) |
| Total expenditure | (1,715) | (4,404) | (6,119) |
Profit before finance costs and taxation | 2,516 | 25,795 | 28,311 |
Finance costs | (864) | (7,778) | (8,642) |
| |||
Profit before taxation | 1,652 | 18,017 | 19,669 |
Taxation | - | - | - |
Profit for year/total comprehensive income | 1,652 | 18,017 | 19,669 |
| |||
Return per Ordinary Share | 2.30p | 25.08p | 27.38p |
CT Private Equity Trust PLC
Statement of Comprehensive Income for the
year ended 31 December 2023
| (Audited)
| |||
Revenue £'000 | Capital £'000 | Total £'000
| |
| Income | |||
Gains on investments held at fair value | - | 25,226 | 25,226 |
Exchange gains | - | 863 | 863 |
Investment income | 2,703 | - | 2,703 |
Other income | 689 | - | 689 |
| Total income | 3,392 | 26,089 | 29,481 |
| Expenditure | |||
Investment management fee - basic fee | (474) | (4,263) | (4,737) |
Investment management fee - performance fee | - | (4,767) | (4,767) |
Other expenses | (1,064) | - | (1,064) |
| Total expenditure | (1,538) | (9,030) | (10,568) |
Profit before finance costs and taxation | 1,854 | 17,059 | 18,913 |
Finance costs | (513) | (4,616) | (5,129) |
| |||
Profit before taxation | 1,341 | 12,443 | 13,784 |
Taxation | - | - | - |
Profit for year/total comprehensive income | 1,341 | 12,443 | 13,784 |
| |||
Return per Ordinary Share | 1.84p | 17.08p | 18.92p |
CT Private Equity Trust PLC
Balance Sheet
| As at 31 December 2024 (Unaudited) | As at 31 December 2023 (Audited)
|
| £'000 | £'000 |
Non-current assets |
| |
Investments at fair value through profit or loss | 584,097 | 605,603 |
584,097 | 605,603 | |
Current assets | ||
Other receivables | 1,110 | 841 |
Cash and cash equivalents | 16,000 | 9,879 |
17,110 | 10,720 | |
Current liabilities | ||
Other payables Interest-bearing bank loan | (3,859) (43,944) | (8,121) (97,109) |
| (47,803) | (105,230) |
Net current liabilities | (30,693) | (94,510) |
Total assets less current liabilities | 553,404 | 511,093 |
| ||
| Non-current liabilities | ||
Interest-bearing bank loan | (48,575) | - |
Net assets | 504,829 | 511,093 |
| ||
Equity | ||
Called-up ordinary share capital | 739 | 739 |
Share premium account | 2,527 | 2,527 |
Special distributable capital reserve | 3,818 | 9,597 |
Special distributable revenue reserve | 31,403 | 31,403 |
Capital redemption reserve | 1,335 | 1,335 |
Capital reserve | 465,007 | 465,492 |
Shareholders' funds | 504,829 | 511,093 |
Net asset value per Ordinary Share | 706.03p | 702.50p |
CT Private Equity Trust PLC
Statement of Changes in Equity
Share Capital | Share Premium Account | Special Distributable Capital Reserve | Special Distributable Revenue Reserve | Capital Redemption Reserve | Capital Reserve | Revenue Reserve | Total | |
£'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | £'000 | |
For the year ended 31 December 2024 (unaudited)
| ||||||||
Net assets at 1 January 2024 | 739 | 2,527 | 9,597 | 31,403 | 1,335 | 465,492 | - | 511,093 |
Buyback of ordinary shares | - | - | (5,779) | - | - | - | - | (5,779) |
Profit for the year/total comprehensive income | - | - | - | - | - | 18,017 | 1,652 | 19,669 |
Dividends paid | - | - | - | - | - | (18,502) | (1,652) | (20,154) |
Net assets at 31 December 2024 | 739 | 2,527 | 3,818 | 31,403 | 1,335 | 465,007 | - | 504,829 |
For the year ended 31 December 2023 (audited)
| ||||||||
Net assets at 1 January 2023 | 739 | 2,527 | 10,026 | 31,403 | 1,335 | 471,645 | - | 517,675 |
Buyback of ordinary shares | - | - | (429) | - | - | - | - | (429) |
Profit for the year/total comprehensive income | - | - | - | - | - | 12,443 | 1,341 | 13,784 |
Dividends paid | - | - | - | - | - | (18,596) | (1,341) | (19,937) |
Net assets at 31 December 2023 | 739 | 2,527 | 9,597 | 31,403 | 1,335 | 465,492 | - | 511,093 |
CT Private Equity Trust PLC
Statement of Cash Flows
| Year ended 31 December 2024 (Unaudited) | Year ended 31 December 2023 (Audited) | |
|
|
| |
| £000 | £000 | |
Operating activities | |||
Profit before taxation | 19,669 | 13,784 | |
Adjustments for: Gains on disposals of investments |
(58,769) |
(26,349) | |
Losses on account of fair value movement | 33,625 | 1,123 | |
Exchange differences | (5,055) | (863) | |
Interest Income | (961) | (689) | |
Interest received | 937 | 668 | |
Finance costs | 8,642 | 5,129 | |
Increase in other receivables | (266) | (8) | |
Decrease in other payables | (4,082) | (497) | |
Net cash outflow from operating activities |
(6,260) |
(7,702) | |
| |||
Investing activities | |||
Purchases of investments | (58,712) | (110,784) | |
Sales of investments | 105,362 | 58,964 | |
Net cash inflow/(outflow) from investing activities |
46,650 |
(51,820) | |
| Financing activities | |||
| Drawdown of bank loans | 2,182 | 59,023 | |
| Arrangement costs of loan facility | (1,468) | (27) | |
Interest paid | (8,209) | (3,995) | |
Equity dividends paid | (20,154) | (19,937) | |
Buyback of ordinary shares | (5,779) | (429) | |
Net cash (outflow)/inflow from financing activities |
(33,428) |
34,635 | |
Net increase/(decrease) in cash and cash equivalents |
6,962 |
(24,887) | |
Currency (losses)/gains | (841) | 306 | |
Net increase/(decrease) in cash and cash equivalents |
6,121 |
(24,581) | |
Opening cash and cash equivalents | 9,879 | 34,460 | |
Closing cash and cash equivalents | 16,000 | 9,879 | |
Notes (unaudited)
1. The unaudited financial results, which were approved by the Board on 27 March 2025, have been prepared in accordance with UK adopted international accounting standards. Where presentation guidance set out in the Statement of Recommended Practice "Financial Statements of Investment Trust Companies and Venture Capital Trusts" ('SORP') issued by the Association of Investment Companies is consistent with the requirements of international accounting standards, the Directors have sought to prepare the financial statements on a basis compliant with the recommendations of the SORP. The Directors have assessed Going Concern and consider it the appropriate basis for the figures presented in the announcement.
The accounting policies adopted are consistent with those of the previous financial year.
Standards issued but not yet effective
There are no standards or amendments to standards not yet effective that are relevant to the Company and should be disclosed.
2. Returns per Ordinary Share are based on the following weighted average number of shares in issue during the year: 71,845,834 (2023: 72,838,637).
The net asset value per Ordinary Share is based on the following number of shares in issue at the year-end: 71,502,938 (2023: 72,752,938).
During the year ended 31 December 2024, the Company issued nil Ordinary Shares. During the previous year ended 31 December 2023, the Company issued nil Ordinary Shares. During the year ended 31 December 2024, the Company bought back 1,250,000 Ordinary Shares to be held in treasury. During the previous year ended 31 December 2023, the Company bought back 92,000 Ordinary Shares to be held in treasury.
3. The Board has proposed an interim dividend of 7.01 pence per Ordinary Share, payable on 30 April 2025 to those Shareholders on the register on 11 April 2025 with an ex-dividend date of 10 April 2025.
4. This results announcement is based on the Company's unaudited financial statements for the year ended 31 December 2024 which have been prepared in accordance with UK adopted international accounting standards.
5. This announcement is not the Company's statutory accounts. The full audited accounts for the year ended 31 December 2023, which were unqualified and had no emphasis of matters, have been lodged with the Registrar of Companies. The statutory accounts for the year to 31 December 2024 (on which the audit report has not yet been signed) will be delivered to the Registrar of Companies following the Company's Annual General Meeting which will be held at Cannon Place, 78 Cannon Street, London, EC4N 6AG on 29 May 2025 at 13.00.
6. The Annual Report and Accounts for the year will be sent to Shareholders and will be available for inspection at the Company's registered office, Quartermile 4, 7a Nightingale Way, Edinburgh, EH3 9EG and the Company's website www.ctprivateequitytrust.com. The Company intends to issue a subsequent annual financial report announcement.
For more information, please contact:
Hamish Mair (Investment Manager) | 0131 573 8300 |
Scott McEllen (Company Secretary) | 0131 573 8300 |
Appendix: Alternative Performance Measures
The Company uses the following Alternative Performance Measures ('APMs'):
Discount (or premium) - If the share price of an Investment Trust is less than its Net Asset Value per share, the shares are trading at a discount. If the share price is greater than the Net Asset Value per share, the shares are trading at a premium.
31 December 2024 | 31 December 2023 | ||
Net Asset Value per share (pence) | (a) | 706.03 | 702.50 |
Share price per share (pence) | (b) | 488.00 | 468.00 |
Discount (c=(b-a)/a) | (c) | 30.9% | 33.4% |
Dividend Yield - The dividends declared for the year divided by the share price at the year end.
Gearing - This is the ratio of the borrowings less cash of the Company to its total assets less current liabilities (excluding borrowings and cash). Borrowings may include: preference shares; debentures; overdrafts and short and long-term loans from banks; and derivative contracts. If the Company has cash assets, these may be assumed either to net off against borrowings, giving a "net" or "effective" gearing percentage, or to be used to buy investments, giving a "gross" or "fully invested" gearing figure. Where cash assets exceed borrowings, the Company is described as having "net cash".
31 December 2024 | 31 December 2023 | ||
£'000 | £'000 | ||
Borrowings less cash | (a) | 76,519 | 87,230 |
Total assets less current liabilities (excluding borrowings and cash) | (b) | 581,348 | 598,323 |
Gearing (c=a/b) | (c) | 13.2% | 14.6% |
Ongoing Charges - All operating costs expected to be incurred in future and that are payable by the Company expressed as a proportion of the average Net Assets of the Company over the reporting year. The costs of buying and selling investments are excluded, as are interest costs, taxation, performance fees, non-recurring costs and the costs of buying back or issuing Ordinary Shares. Ongoing charges of the Company's underlying investments are also excluded.
Year to 31 December 2024 | Year to 31 December 2023 | |
Ongoing charges (£'000) | 6,119 | 5,801 |
Ongoing charges as a percentage of average assets: | 1.2% | 1.1% |
Ongoing charges (including performance fees) (£'000) | 6,119 | 10,568 |
Ongoing charges (including performance fees) as a percentage of average net assets: |
1.2% |
2.1% |
Average net assets (£'000) | 499,457 | 508,718 |
Total Return - The return to Shareholders calculated on a per share basis by adding dividends paid in the period to the increase or decrease in the Share Price or NAV. The dividends are assumed to have been reinvested in the form of Ordinary Shares or Net Assets.
Year to 31 December 2024 | Year to 31 December 2023 | |
NAV per share at start of year (pence) | 702.50 | 710.65 |
NAV per share at end of year (pence) | 706.03 | 702.50 |
Change in year | +0.5% | -1.1% |
Impact of dividend reinvestments | +4.1% | +3.9% |
Total NAV return for the year | +4.6% | +2.8% |
Year to 31 December 2024 | Year to 31 December 2023 | |
Share price per share at start of year (pence) | 468.00 | 423.00 |
Share price per share at end of year (pence) | 488.00 | 468.00 |
Change in year | +4.3% | +10.6% |
Impact of dividend reinvestments | +6.6% | +7.0% |
Total share price return for the year | +10.9% | +17.6% |
Related Shares:
Ct Priv. Ord